Immunohistochemistry (IHC) Market in terms of revenue was estimated to be worth $3.2 billion in 2023 and is poised to reach $4.7 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Market growth is largely driven by the increased population of geriatric and the increased incidence of cancer cases, technological advancement of IHC, and availability of reimbursements for IHC tests. However, the presence of alternative test, and the high degree of consolidation in the market by the major market players is expected to restrain the growth of this market during the forecast period.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939
The Kits product segment accounted for the highest growth rate in the immunohistochemistry market, by product, during the forecast period
In 2022, the Kits product segment accounted for the highest growth rate of the immunohistochemistry market. The demand for complete solutions from a single reliable product provider, like closed-system reagents with calibrated measurements of the required test quantity of reagents and controls among diagnostic laboratories, hospitals, research institutes, and other end users, is growing. Moreover, ready-to-use kits simplify the IHC process by rectifying the initial time-consuming selections of primary antibodies and appropriate stains. This is rapidly increasing the growth of the immunohistochemistry kits market.
Forensics applications segment accounted for the smallest share of the application segment
Based on application, the IHC market is segmented into diagnostic, research, and forensic applications. The forensics application segment accounted for the smallest this market in 2022. In forensics, IHC can play an important role in determining the cause of death. Immunohistochemistry carried out on post-mortem samples helps in determining age-related brain disease (Alzheimer’s, strokes) and trauma (often accidental, from falls) and their respective roles in the cause of death. However, its applications in forensic pathology are generally limited to ruling in or out natural disease. This is due to degradation of tissue of a body where the time from death to autopsy is several days.
Hospitals & Diagnostic Laboratories segment accounted for the largest share of the end user segment
Based on end user, the IHC market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share of the IHC market in 2022. The growing number of specialty diagnostic tests performed in hospital laboratories, the increasing number of in-house diagnostic procedures in hospitals, and the rising trend of establishing in-house diagnostic capabilities in hospitals to provide time-bound and affordable patient services are factors driving the growth of this market segment.
Asia Pacific: The fastest-growing region in the immunohistochemistry market.
Based on the region, the immunohistochemistry market is broadly segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. APAC is expected to register the fastest growth rate during the forecast period. The economic growth in the countries of this region, large population base, the rising prevalence of chronic diseases, the rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of IHC test are the major factors driving the growth of the Immunohistochemistry market in the Asia Pacific region.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939
Immunohistochemistry (IHC) Market Dynamics:
Drivers:
- Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
- Technological advancements in IHC
- Availability of reimbursements for IHC tests
Restraints:
- High degree of consolidation
Opportunities:
- Increasing demand for personalized medicine
- Growing significance of companion diagnostics
- Growth opportunities in emerging countries
Challenges:
- Dearth of skilled professionals
- Product failures and recalls
Key Market Players:
Prominent players operating in the global immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).
Recent Developments:
- In February 2023, F. Hoffman-La Roche AG (Switzerland) launched IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and the ATRX Rabbit Polyclonal Antibody for use in BenchMark series of instrument for detection of brain cancer.
- In October 2022, F. Hoffman-La Roche AG (Switzerland) received US FDA approval for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody use as companion diagnostic test to identify metastatic breast cancer patients with low HER2 expression.
- In April 2023, Danaher Corporation (US), subsidiary Leica Biosystems received FDA clearance for BOND MMR Antibody Panel, for detection of colorectal cancer.
- In November 2022, Danaher Corporation (US), subsidiary Leica Biosystems Nussloch GmbH acquired Cell IDx, Inc. an immunodiagnostic company offering chromogenic and fluorescent multiplex IHC biomarker profiling products.
- In January 2023, Agilent Technologies, Inc. (US) signed a partnership deal with Akoya Biosciences for developing chromogenic and immunofluorescent multiplex assays. These assays will be used for immunohistochemistry diagnostic solutions.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121632939
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/immunohistochemistry-market-121632939.html